Biogen Revenue 2006-2021 | BIIB

Biogen annual/quarterly revenue history and growth rate from 2006 to 2021. Revenue can be defined as the amount of money a company receives from its customers in exchange for the sales of goods or services. Revenue is the top line item on an income statement from which all costs and expenses are subtracted to arrive at net income.
  • Biogen revenue for the quarter ending September 30, 2021 was $2.779B, a 17.69% decline year-over-year.
  • Biogen revenue for the twelve months ending September 30, 2021 was $11.101B, a 22.17% decline year-over-year.
  • Biogen annual revenue for 2020 was $13.445B, a 6.49% decline from 2019.
  • Biogen annual revenue for 2019 was $14.378B, a 6.88% increase from 2018.
  • Biogen annual revenue for 2018 was $13.453B, a 9.61% increase from 2017.
Biogen Annual Revenue
(Millions of US $)
2020 $13,445
2019 $14,378
2018 $13,453
2017 $12,274
2016 $11,449
2015 $10,764
2014 $9,703
2013 $6,932
2012 $5,516
2011 $5,049
2010 $4,716
2009 $4,377
2008 $4,098
2007 $3,172
2006 $2,683
2005 $2,423
Biogen Quarterly Revenue
(Millions of US $)
2021-09-30 $2,779
2021-06-30 $2,775
2021-03-31 $2,694
2020-12-31 $2,853
2020-09-30 $3,376
2020-06-30 $3,682
2020-03-31 $3,534
2019-12-31 $3,671
2019-09-30 $3,600
2019-06-30 $3,617
2019-03-31 $3,490
2018-12-31 $3,526
2018-09-30 $3,439
2018-06-30 $3,357
2018-03-31 $3,131
2017-12-31 $3,307
2017-09-30 $3,078
2017-06-30 $3,078
2017-03-31 $2,811
2016-12-31 $2,872
2016-09-30 $2,956
2016-06-30 $2,894
2016-03-31 $2,727
2015-12-31 $2,839
2015-09-30 $2,778
2015-06-30 $2,592
2015-03-31 $2,555
2014-12-31 $2,641
2014-09-30 $2,511
2014-06-30 $2,421
2014-03-31 $2,130
2013-12-31 $1,966
2013-09-30 $1,828
2013-06-30 $1,723
2013-03-31 $1,415
2012-12-31 $1,418
2012-09-30 $1,386
2012-06-30 $1,421
2012-03-31 $1,292
2011-12-31 $1,327
2011-09-30 $1,310
2011-06-30 $1,209
2011-03-31 $1,203
2010-12-31 $1,219
2010-09-30 $1,176
2010-06-30 $1,213
2010-03-31 $1,109
2009-12-31 $1,127
2009-09-30 $1,121
2009-06-30 $1,093
2009-03-31 $1,036
2008-12-31 $1,069
2008-09-30 $1,093
2008-06-30 $993
2008-03-31 $942
2007-12-31 $893
2007-09-30 $789
2007-06-30 $773
2007-03-31 $716
2006-12-31 $708
2006-09-30 $703
2006-06-30 $660
2006-03-31 $611
2005-12-31 $633
2005-09-30 $596
2005-06-30 $606
2005-03-31 $588
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $32.892B $13.445B
Biogen is a leading biopharmaceutical company engaged in the research, development and marketing of targeted therapies for the treatment of cancer, autoimmune and inflammatory diseases. The company owns industry leading brands for the treatment of multiple sclerosis, next-generation treatments for hemophilia, and a deep clinical pipeline ranging from Alzheimer's disease, lupus nephritis to neuropathic pain.
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $125.010B 7.90
Bio-Rad Laboratories (BIO.B) United States $22.443B 45.55
QIAGEN (QGEN) Netherlands $12.357B 20.93
Biohaven Pharmaceutical Holding (BHVN) United States $6.783B 0.00
Arcus Biosciences (RCUS) United States $3.105B 0.00
Emergent Biosolutions (EBS) United States $2.254B 8.10
ADC Therapeutics SA (ADCT) Switzerland $1.478B 0.00
Myovant Sciences (MYOV) United Kingdom $1.368B 0.00
Zymeworks (ZYME) Canada $0.861B 0.00
Ambrx Biopharma (AMAM) United States $0.337B 0.00
SQZ Biotechnologies (SQZ) United States $0.319B 0.00
Enzo Biochem (ENZ) United States $0.162B 15.90